Optimer signs $90 million-plus deal with Astellas for Dificid in Japan
This article was originally published in Scrip
Executive Summary
Optimer Pharmaceuticals Inc. will get up to $90 million plus revenue from product sales in its partnership with Astellas Pharma Inc. to develop and commercialize Dificid (fidaxomicin) in Japan, a market where the oral antibiotic approved in the US and EU to treat Clostridium difficile-associated diarrhoea (CDAD) could be a blockbuster, according to Optimer president and CEO Pedro Lichtinger.